Daré Bioscience Provides Update On Activities To Support Commercial Launch Of XACIATO Vaginal Gel, 2%, FDA-Approved Treatment For Females 12 And Older With Bacterial Vaginosis, And Announced That Organon Will Pay Daré $1M In July 2023
Portfolio Pulse from Happy Mohamed
Daré Bioscience (NASDAQ:DARE) is preparing for the commercial launch of XACIATO, a treatment for bacterial vaginosis, in collaboration with Organon (NYSE:OGN). Organon will pay Daré $1 million in July 2023 and $1.8 million upon the first commercial sale of XACIATO. Daré received a $10 million upfront payment from Organon in 2022 and is eligible for additional milestone payments of up to $180 million and tiered double-digit royalties based on net sales.
July 05, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience is set to receive significant payments from Organon related to the launch of XACIATO, which could boost its revenues and profitability.
The news of the upcoming payments from Organon, including the $1 million in July 2023 and $1.8 million upon the first commercial sale of XACIATO, as well as potential future milestone payments of up to $180 million, is likely to have a positive impact on Daré's stock as it indicates potential for increased revenues and profitability.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Organon's collaboration with Daré Bioscience for the launch of XACIATO could potentially expand its product portfolio and market reach.
The news of Organon's collaboration with Daré for the launch of XACIATO is likely to have a positive impact on Organon's stock as it indicates potential for product portfolio expansion and increased market reach. However, the payments to Daré could also impact Organon's short-term profitability.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80